Litigation Details for Clarus Therapeutics Holdings, Inc. (Bankr. D. Del. 2022)
✉ Email this page to a colleague
Clarus Therapeutics Holdings, Inc. (Bankr. D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-09-05 |
| Court | United States Bankruptcy Court, D. Delaware | Date Terminated | |
| Cause | Assigned To | Mary F. Walrath | |
| Jury Demand | Referred To | ||
| Parties | STRETTO | ||
| Patents | 10,543,219; 8,241,664; 8,492,369; 8,778,916 | ||
| Attorneys | Jonathan Doolittle | ||
| Firms | DLA Piper LLP (US) | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Clarus Therapeutics Holdings, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Clarus Therapeutics Holdings, Inc. (Bankr. D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-09-05 | 3 | Affidavit/Declaration in Support of First Day Motion (BF) | in December 2030, as well as U.S. Patent Nos. 8,778,916, 10,543,219, 10,617,696, and 11,179,403 each of…Debtors’ U.S. patent portfolio on JATENZO currently includes seven issued patents: U.S. Patent No. 11,179,402…JATENZO. Clarus’ U.S. patent portfolio on JATENZO currently includes seven issued patents.5 In addition, Clarus…in April 2026, U.S. Patent No. 8,241,664, which expires in March 2029; U.S. Patent No. 8,492,369, which… Clarus has several patent applications pending in the United States and other countries that, if issued | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
